Amgen Ventures

Amgen Ventures is the corporate venture capital arm of Amgen Inc. (NASDAQ: AMGN), one of the world's largest biotechnology companies. Founded in 2004 and based in San Francisco — with additional offices in Seattle, Thousand Oaks, and Cambridge — the fund has invested over $1 billion across its 20-year history, backing early and later-stage biotech companies developing human therapeutics. Core therapeutic focus areas include oncology, inflammation, neuroscience, and cardiovascular disease. The fund deploys $2 to $3 million per transaction, with investments reaching up to $10 million per company across Seed through Series B rounds. With 80 investments spanning North America and Europe, Amgen Ventures supports novel modalities, platform technologies, and digital health solutions. The portfolio is led by Samantha Palmer, Executive Director and Head of Amgen Ventures, who was named to the 2024 Powerlist of 100 leading corporate venturing professionals. Amgen Ventures occupies a distinctive position in corporate venture: portfolio companies gain direct access to Amgen's extensive research capabilities, manufacturing infrastructure, and scientific expertise. In return, Amgen gains early visibility into external innovation across emerging therapeutic areas. This mutual exchange — strategic access for capital — underpins the fund's model, making it more than a financial investor and a genuine partner in building the next generation of biotech companies.